103 Views | 29 Downloads
Nabil F. Saba, nfsaba@emory.edu
N.F.S. conceived, designed and implemented the study, wrote the paper and analyzed the generated data. A.E. collected the data. A.M.-V. and Y.L. performed the statistical analysis. K.M. performed the PD-L1 and p16 testing. M.A. collected and analyzed the data. A.C.T., M.Z.H.F. and R.C. performed the WES and TMB calculations. C.E.S., M.P., N.C.S., W.S., J.E.B., S.R., J.R., M.M., J.M., K.K. and D.M.S. enrolled and treated patients on the study, collected the data and reviewed the paper. G.Z.H. and Y.T. performed the intratumoral CD8+ analysis. C.H.C. implemented the study at Moffitt Cancer Center, collected, and analyzed the data and reviewed the paper. All authors contributed to the revision of the paper.
This research was supported by a grant from Exelixis to N.F.S. The research reported in this publication was supported in part by the Biostatistics Shared Resource of Winship Cancer Institute of Emory University and National Institutes of Health (IH)/NCI under award no. P30CA138292. The computational resources used were partially funded by the NIH Shared Instrumentation grant no. 1S10OD021644-01A1; this research was partially supported by a Huntsman Cancer Institute at the University of Utah Cancer Center Support grant no. P30CA042014, the National Institute of Dental and Craniofacial Research (no. R01DE030508 to A.C.T. and C.H.C.) and the James and Esther King Biomedical Research grant (no. 21K04 to C.H.C. and A.C.T.). The biomarker study was partially supported by a Winship Invest$ Team Science Award (to Y.T. and N.F.S.), I3 Nexus award from Emory School of Medicine (to Y.T. and N.F.S.) and the National Institute of Dental and Craniofacial Research grant no. R01DE028351 (to Y.T.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The authors thank A. Hammond for her editorial feedback.
N.F.S. reports advisory roles for Merck, AZ, Eisai, Exelixis, Vaccinex, BNT and CUE. J.E.B. reports advisory roles for Galera Therapeutics and Castle Biosciences. N.C.S. reports research funding from Astex. C.H.C. reports advisory board participation for Merck, Exelixis, Fulgent, Genmab and Brooklyn ImmunoTherapeutics. The other authors declare no competing interests.